biotech
2024 Biotech IPOs: Insights and Trends
Biotech IPOs, 2024 IPO trends, biopharma sector, initial public offerings, venture capital investment, healthcare innovation.
Belharra Biotech Cuts 21 Jobs Amid Industry-Wide Restructuring
Belharra Biotech, layoffs, chemoproteomics, biotech industry, restructuring
Dimension Secures $500M for Second Fund, Focusing on the Intersection of Science and Technology
Dimension, Venture Capital, Science, Technology, Biotech, AI, Machine Learning, Life Sciences, Innovation
GSK Expands Eastern Partnerships with $30M Option on DualityBio’s Preclinical ADC
GSK, DualityBio, ADC, Preclinical, Biotech, Pharmaceutical Partnerships
Relay Therapeutics Partners with Elevar Therapeutics in $500M Deal for Lirafugratinib in Rare Cancer Treatment
Relay Therapeutics, Elevar Therapeutics, Lirafugratinib, FGFR2-Driven Cholangiocarcinoma, Rare Cancer Treatment, Biotech Partnership
Gilead Partners with Tubulis for Solid Tumor ADC Development in Deal Worth Up to $465M
Gilead, Tubulis, ADC, Solid Tumor, Biotech, Partnership
Sarepta Therapeutics and Arrowhead Pharmaceuticals Enter $10 Billion Collaboration for Rare Disease Treatments
Sarepta Therapeutics, Arrowhead Pharmaceuticals, RNAi, Rare Diseases, Genetic Medicine, Collaboration Agreement, Biotech, Pharmaceutical Industry
Metsera Secures $215M to Accelerate Obesity Drug Development
Metsera, Obesity Drug, Funding, Biotech, GLP-1, Metabolic Disease
Insights from Jade CEO: Reverse Merger and IgAN Drug Development
Jade CEO, Reverse Merger, IgAN Drugs, Pharmaceutical Development, Biotech Mergers
Biogen Expands Portfolio with Neomorph Molecular Glues Deal Worth Up to $1.45 Billion
Biogen, Neomorph, Molecular Glues, Biotech Deal, Pharmaceutical Acquisition